Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 0.56 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.37 |
| ▸ | CCNK | O75909 | 1/20 | 0.34 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15906074 | 0.88 | JAK2 (0.55) | JAK2NTRK1MAPK14 | |
| SCHEMBL4301490 | 0.86 | JAK2 (0.56) | JAK2NTRK1MAPK14CCNKCDK12 | |
| SCHEMBL4106214 | 0.85 | JAK2 (0.53) | JAK2NTRK1MAPK14CCNKCDK12 | |
| SCHEMBL4102105 | 0.80 | NTRK1 (0.55) | JAK2NTRK1MAPK14 | |
| SCHEMBL4104877 | 0.76 | MAPK14 (0.43) | JAK2NTRK1MAPK14CCNKCDK12 | |
| SCHEMBL946873 | 0.76 | JAK2 (0.52) | JAK2NTRK1MAPK14CCNKCDK12 | |
| SCHEMBL4106164 | 0.75 | JAK2 (0.50) | JAK2NTRK1 | |
| SCHEMBL4306726 | 0.74 | MAPK14 (0.45) | JAK2NTRK1MAPK14CCNKCDK12 | |
| SCHEMBL19441276 | 0.74 | MAPK14 (0.41) | JAK2NTRK1MAPK14CCNKCDK12 | |
| SCHEMBL2878758 | 0.73 | MAPK14 (0.44) | JAK2NTRK1MAPK14CCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9782415-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170119770-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170119770-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | TXK, FRK, LTK | JAK2 124/4885NTRK1 7/4885MAPK14 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.